Bernd Seizinger Buys Shares of APRE $APRE
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Bernd Seizinger, insider at Aprea Therapeutics, Inc. ($APRE), bought 3,135 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Aprea Therapeutics, Inc. Stock Down 13.0%
Shares of Aprea Therapeutics, Inc. ($APRE) traded around $0.73 on Thursday, down 13.0% for the day.
Aprea Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Get Aprea Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $APRE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.